Multiple myeloma clinical trial closes early

Apr 05, 2007

Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.

The study led by the Eastern Cooperative Oncology Group (ECOG) and supported by the National Cancer Institute compared combination treatment of oral medications lenalidomide and either high- or low-dose dexamethasone in 445 patients with newly-diagnosed myeloma. Lenalidomide plus high-dose dexamethasone had a one-year survival rate of 86 percent. The comparative therapy using low-dose dexamethasone showed a significantly higher 96.5 percent overall survival rate at one year, with much less toxicity.

"In my opinion, this is the best one-year survival data that I’ve seen in a large phase 3 study in myeloma," says Vincent Rajkumar, M.D., Mayo Clinic hematologist and primary investigator of the ECOG study. "This is a major advance in the treatment of this cancer."

All patients on the high-dose dexamethasone arm of the clinical trial will be moved to the low-dose arm. A successor study using lenalidomide plus high-dose dexamethasone was closed early as a result of these findings.

Source: Mayo Clinic

Explore further: US spends more on cancer care, saves fewer lives than Western Europe

add to favorites email to friend print save as pdf

Related Stories

Living in the genetic comfort zone

7 hours ago

The information encoded in the DNA of an organism is not sufficient to determine the expression pattern of genes. This fact has been known even before the discovery of epigenetics, which refers to external ...

'Bright spot' on Ceres has dimmer companion

8 hours ago

Dwarf planet Ceres continues to puzzle scientists as NASA's Dawn spacecraft gets closer to being captured into orbit around the object. The latest images from Dawn, taken nearly 29,000 miles (46,000 kilometers) ...

Key facts on US 'open Internet' regulation

8 hours ago

A landmark ruling by the US Federal Communications Commission seeks to enshrine the notion of an "open Internet," or "net neutrality." Here are key points:

Spotify deals with random shuffle and we mortals

8 hours ago

How do we mortals perceive random sequences? An entry in the question-and-answer site Quora focused on a question involving a music-streaming service Spotify. That question signifies how we perceive what ...

Recommended for you

Protein may be key to cancer's deadly resurgences

2 hours ago

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently ...

US women's awareness of breast density varies

18 hours ago

Disparities in the level of awareness and knowledge of breast density exist among U.S. women, according to the results of a Mayo Clinic study published in the Journal of Clinical Oncology.

Study shows why some brain cancers resist treatment

19 hours ago

Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.